“This
is particularly burdensome for scientists in developing countries like Jamaica,
where resources are limited and the filing and maintenance of patents are very
expensive”
Dr. Henry Lowe
commenting on his being granted a patent for a unique synthesis method for
called Dicinnamoyl-Glycerol Esters
Dr.
Henry Lowe's BTRDI (Bio-Tech R&D Institute) in collaboration with Dr. L.
Bryant of the University of Maryland Institute of Human Virology (IHV) has made
yet another breakthrough for which they've been awarded a patent.
 |
They've
been granted a patent for a novel synthesis method for making a new group of
chemical compounds called Dicinnamoyl-Glycerol Esters extracted from the Ball Moss Plant (Tillandsia recurvata) as reported in
the article “US
Grants Likely Cancer Cure Patent To Jamaican Scientist”, published Monday
March 23, 2015 by Gary Spaulding, The
Jamaica Gleaner.
Dr.
Henry Lowe of BTRDI and Dr Joseph Bryant at the University of Maryland
Institute of Human Virology (IHV) who
were formally granted the patent by the US Patent Office, numbered US8907117, also
published as US20130210913
A1 on Tuesday December 9, 2014, only made this achievement known in March
2015.
What
makes this latest discovery, for which they'd been awarded a patent after four
(4) patent years of waiting, is that these Dicinnamoyl-Glycerol Esters and
their mirror isomers, be they cis or trans-isomers have activity against
various cancers.
Not
only that, but these Dicinnamoyl-Glycerol Esters extracted from the Ball Moss Plant (Tillandsia recurvata) also had shown
activity against HIV-AIDS (Human Immuno Deficiency Virus Acquired
Immuno-Deficiency Disease).
Dr. Henry Lowe and the
Ball Moss Plant – Patent US8907117 for HIV and Cancer Cure
Ball Moss Plant (Tillandsia recurvata) commonly known
as Ball Moss is actually a flowering plant. It not a member of the Moss family,
which is really a parasitic plant like the Mistletoe, but actually grows in
symbiosis on a host plant or even on JPS Co Wires, basically making it an
epiphyte.
It
needs little light and airflow but uses the high humidity to extract water.
Unlike the Lignum Vitae, it's not endemic to Jamaica but is peculiar to this
region, found mostly in the Southern part of North America, Central America and
the Caribbean and part of South America
This
activity against Cancer and HIV/AIDS was demonstrated via “in-vitro” Lab Rat assays
as far back as 2008 as reported in the article “Cancer,
HIV cure nearer”, published Monday, July 07, 2008 BY Ross Sheil Observer Online co-ordinator,
The Jamaica Observer.
The
Patent granted by the US Patent Office, numbered US8907117, also
published as US20130210913
A1, is registered to Dr. Henry Lowe and Dr. Joseph L. Bryant. On examining
the Patents, it clearly lays out the synthesis steps in a series of four
images, reproduced here, which should be of interest to Organic Chemistry
students such as myself.
 |
Dr.
Henry Lowe had already discovered anti-HIV properties in the Lignum Vitae flower, the National Flower of Jamaica
back in August 2014 as noted in my blog article
entitled
More
recently, he discovered similar anti-HIV activity in the Guinea Hen Weed (Petiveria Alliacea) extract, Dibenzyl
Trisulphide (C14H14S3), which was announced in
early January 2015 as reported in my blog article
entitled “Dr.
Henry Lowe and BTRDI Team discover Guinea Hen Weed active against HIV -
Chikungunya Virus Treatment potential as Dr Lawrence Williams Cancer Cure also
kills HIV”.
So
how did a Dr. Henry Lowe and his BTRDI, the parent company of Medicanja, his medical Marijuana
company and new applicant for an IPO (Initial Public Offering) as noted in my blog article
entitled “Dr.
Henry Lowe Medicanja's parent BTRDI launching IPO in 2015 - Why P.J. Patterson
“fly the gate” for Hemp and Marijuana products to cure 84 ailments”,
achieve this amazing feat?
Dr. Henry Lowe and the
Ball Moss Plant Patent – From Publication to Patent Filing
Dr.
Henry Lowe began his research into the synthesis of Dicinnamoyl-Glycerol Esters
after discovering along with partner Dr Joseph Bryant at the University of
Maryland Institute of Human Virology (IHV) back in 2008 that the active
ingredients in the Ball
Moss Plant (Tillandsia recurvata)
had activity against Cancers and HIV/AIDS as noted in the article “Cancer,
HIV cure nearer”, published Monday, July 07, 2008 BY Ross Sheil Observer Online
co-ordinator, The Jamaica
Observer.
 |
Still,
many Jamaicans, including the Jamaica Urological Society in December 2010, were
cautious in their optimism about the effectiveness of these newly discovered
group of active compounds in the Ball Moss Plant (Tillandsia recurvata) as stated in
the article “'Cancer
drug from Jamaican plant overhyped' – urologists”, published Wednesday,
December 08, 2010, The Jamaica
Observer.
Their
optimism was most likely because of their doubts as to how effective these new
compounds were. This especially as Dr. Lowe and Dr. Bryant had declared them to
be more potent and with less side-effect than Taxol, then the leading
anti-cancer drug on the market and only after having tested them on lab rats
and having undergone no clinical trials on humans.
Still
undeterred, he published his work in 2012 in a series of scientific journals a
reported in the article “Henry
Lowe makes another step forward in cancer research”, published Sunday,
September 30, 2012 BY VERNON
DAVIDSON Executive editor — publications, The Jamaica Observer and then filed
a patent application for his synthesis method of Dicinnamoyl-Glycerol Esters
and their isomers from the Ball
Moss Plant (Tillandsia recurvata).
For
those into reading scientific journals, his published work on the isolation of
Dicinnamoyl-Glycerol Esters from the Ball Moss Plant (Tillandsia recurvata) can be found
in the following journals:
3. NCBI
More
specifically, his works are entitled as thus on these journals:
Still,
Dr. Lowe and company pressed on, not only with research into the Ball Moss Plant (Tillandsia recurvata) but also the develope of Marijuana (Cannabis Sativa) and the extraction of
its active drugs THC (Tetra Hydro Cannabinol) and other bioactive ingredients
that could be used to treat a variety of ailments.
By
December 2013, Dr. Heny Lowe had launched his Medical Marijuana company,
Medicanja as reported in my blog article entitled “Dr.Henry
Lowe launches Medicanja and jump-starts Pharmaceutical Industry in our Back
yard – Pharmaceutical Research Renaissance in Jamaica” as he awaited the granting
of the patent for his synthesis method of Dicinnamoyl-Glycerol Esters and their
isomers from the Ball Moss
Plant (Tillandsia recurvata).
Now
in March 2015, some four (4) years later, Dr. Henry Lowe of BTRDI and Dr Joseph
Bryant at the University of Maryland Institute of Human Virology (IHV) have
finally beign rewarded for their patient long and exhaustive work in the
developement of this extraction method for these unique Dicinnamoyl-Glycerol
Esters from the Ball Moss
Plant (Tillandsia recurvata).
To
quote Dr. Henry Lowe upon announcing the news of the granting of this long
sought patent: “We are pleased to know that it has finally been granted”.
Extraction process for
Dicinnamoyl-Glycerol Esters no secret - Unique patent as Dr. Lowe and Dr.
Bryant recognized anti-HIV and anti-Cancer properties
I
suspect the extraction method is really just the use of ethanol and other
reagents, followed by filtration and then finally centrifugation to separate
the lighter long chain Esters from the heavier organic fractions in Ball Moss Plant (Tillandsia recurvata).
Simple
as that!
What
may be unknown are exact concentration of the reagents used and for how long he
had to do the various processes of filtration to achieve a high yield in
comparison to the original weight of the Ball Moss Plant (Tillandsia recurvata).
|
So
it may have been this ease of extraction that mush have weighed on the minds of
the US Patent Office, as this method probably used standard extraction methods
as well as standard reagents available in any laboratory.
What
mush have swayed their decision was the fact that Dr. Henry Lowe of BTRDI and
Dr Joseph Bryant were the first to recognize the anti-Cancer and anti-HIV properties
of the Dicinnamoyl-Glycerol Esters extracted from the Ball Moss Plant (Tillandsia recurvata).
Not
only that, they were the first to have attempted to extract them for this
purpose and demonstrated via a Lab rat in-vitro assay that it had activity
against cancer cells and the HIV virus. The
US Patent Office must have done an exhaustive search through its database to
determine if this was really the first instance of an extraction of Dicinnamoyl-Glycerol
Esters from the Ball
Moss Plant (Tillandsia recurvata).
Combined,
all these unique factors made the discovery not only unique but the exact process
and reagents involved patentable.
The
Dicinnamoyl-Glycerol Esters extracted from the Ball Moss Plant (Tillandsia recurvata) are currently
in the final stages of preclinical studies. When that is done, they'll undergo
clinical trials and drug development in a long and expensive process that can
cost approximately US$1 to US$1.5 billion and last as long as 10 to 15 years!
More
on the development of these anti-Cancer and anti-HIV from the
Dicinnamoyl-Glycerol Esters extracted from the Ball Moss Plant (Tillandsia recurvata) as BTRDI make
the information available
Here's
the link:
US
Patent Office US8907117
or US20130210913 A1
for Dicinnamoyl-Glycerol Esters extraction from Ball Moss Plant (Tillandsia recurvata)
No comments:
Post a Comment